These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15580401)

  • 1. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
    Ooga H; Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1078-84. PubMed ID: 15580401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
    Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
    Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
    Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
    Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
    Bae SH; Yoon SK; Choi JY; Jang JW; Cho SH; Yang JM; Han NI; Ahn BM; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1527-32. PubMed ID: 16174069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
    Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
    Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
    Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
    Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
    Yao FY; Terrault NA; Freise C; Maslow L; Bass NM
    Hepatology; 2001 Aug; 34(2):411-6. PubMed ID: 11481627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis.
    Zhang FK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):10-5. PubMed ID: 16481275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.